profit from every $100 of sales.
$0$100
Koninklijke Philips
$30.34+0.97% today
+4.9% in 1 year
1-year low $23.811-year high $32.91
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $30.05 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Koninklijke Philips sold, what it kept, and what it did with the cash.
Sales went from €17.8 billion in 2022 to €17.8 billion in 2025, with €895 million of profit last year.
SalesProfit
Koninklijke Philips handed back 65% of the cash it generated last year.
€328M
Free cash flow 2025€504M
Bought back its own shares€0
Paid as dividends€328M
Cash vs. debt€2.8B vs. €7.8B
Koninklijke Philips vs. similar companies
Koninklijke Philips grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Koninklijke Philips | 30.1× · Expensive | ||
 Boston Scientific | 22.2× · Fair price | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price | ||
 Glaukos | No profit yet |
AI analysis
An AI analyst reads Koninklijke Philips's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 17,827 | 18,169 | 18,021 | 17,834 | |
| 7,194 | 7,448 | 7,773 | 8,058 | |
| -177 | -168 | 513 | 1,449 | |
| 115 | 1,041 | 1,849 | 2,600 | |
| -1,608 | -466 | -702 | 895 | |
| -1.68 | -0.49 | -0.75 | 0.94 | |
| 40.4% | 41.0% | 43.1% | 45.2% | |
| -1.0% | -0.9% | 2.8% | 8.1% | |
| -9.0% | -2.6% | -3.9% | 5.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 30,688 | 29,406 | 28,976 | 26,944 |
| Cash | 1,172 | 1,869 | 2,401 | 2,794 |
| Total debt | 7,342 | 7,293 | 7,491 | 7,811 |
| Total liabilities | 17,405 | 17,345 | 16,933 | 15,955 |
| 13,249 | 12,028 | 12,006 | 10,957 | |
| 952 | 949 | 933 | 963 | |
| -5.7% | -0.9% | 1.9% | 6.2% | |
| -12.1% | -3.9% | -5.8% | 8.2% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -173 | 2,136 | 1,569 | 1,172 | |
| 806 | 644 | 676 | 668 | |
| -979 | 1,492 | 893 | 504 | |
| Dividends paid | 412 | 2 | 1 | 328 |
| 187 | 662 | 411 | 0 | |
| 95 | 88 | 96 | 141 |
Valuation
- 30.1×
- 19.6×
- –
- 1.8×
- 1.5×
- 53.4×
- 12.3×
- 1.9%
- 3.3%
- 1.2%
Profitability
- 45.2%
- 8.1%
- 5.0%
- 15.4%
- 5.8%
- 1.4%
- 9.0%
- 3.6%
- 8.0%
- 9.3%
Growth
- +0.0%
- –
- −34.1%
- +3.9%
- +1.5%
Financial health
- 2.0×
- 0.71
- 29.7%
- 4.8×
- 1.32
- 0.90
- 0.65
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 49%of 952
Bottom 45%of 884
Bottom 43%of 601
Bottom 17%of 886
Top 44%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.27 | 0.24 | +12.5% |
| Feb 10, 2026 | 0.70 | 0.57 | +23.9% |
| Nov 4, 2025 | 0.37 | 0.37 | +0.0% |
| Jul 29, 2025 | 0.41 | 0.32 | +29.2% |
| May 6, 2025 | 0.27 | 0.14 | +92.9% |
| Feb 19, 2025 | 0.54 | 0.55 | −1.8% |
| Oct 28, 2024 | 0.35 | 0.35 | +0.0% |
| Jul 29, 2024 | 0.32 | 0.25 | +28.0% |
1.2%of the share price, paid each year
On $1,000 invested$12a year at today's yield, before tax
+3.9%2020 to 2025
Raised1 yearin a row, in our data
Paid per share, each year
$0.91 in 2015 → $0.97 in 2025
How safe it looks
36.6% of its profit
Room to growStretchedMore than it earns: 65.1%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
37No pass
Philip Fisher
37No pass
Peter Lynch
33No pass
Joel Greenblatt
19No pass
Charlie Munger
30No pass
Terry Smith
29No pass
Questions about Koninklijke Philips
Is Koninklijke Philips a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Koninklijke Philips AI analysis
What does Koninklijke Philips do?
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It is in Medical - Devices, based in Amsterdam, Netherlands, with 64,317 employees.
Does Koninklijke Philips pay a dividend?
Yes. At today's price the dividend is 1.2% a year, about 37% of its yearly profit. In 2025 it paid out $328 million in dividends.
Is Koninklijke Philips stock halal?
Yes. Koninklijke Philips passes our halal screen: its business is permitted and its debt is 29% of its market value, under the 30% limit. How we check
How has Koninklijke Philips stock done over the past year?
Up 4.9% over the past twelve months, to $30.34. It traded between $23.81 and $32.91 and is 7.8% below its high.
Who are Koninklijke Philips's competitors?
The largest listed companies in the same industry are Boston Scientific, Steris, Zimmer Biomet Holdings and Glaukos. The peers table on this page compares their profit, growth and price with Koninklijke Philips's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.